Is RMS’s stem cell therapy suitable for all blood types?

Yes. RMS’s iPSC-based stem cell therapy is being designed to work across all blood types, an important practical consideration for any therapy intended to reach a broad patient population.

Blood type compatibility is a significant constraint in many forms of cell and organ transplantation. Just as blood transfusions and organ transplants must be matched to the recipient’s blood type to avoid immune rejection, cell therapies that use donor-derived (allogeneic) cells must account for blood type differences between donor and recipient. Approaches that are restricted to specific blood types cannot be made available to all patients, which limits their scalability and accessibility.

RMS’s diabetes therapy is being developed with universal blood type compatibility as an explicit design goal, in both its autologous approach (where the patient’s own cells are used, eliminating the blood type concern entirely) and its allogeneic approach (where engineering strategies are being employed to broaden immune compatibility beyond blood type restrictions). This commitment to universal accessibility reflects RMS’s broader goal of developing a therapy that can be deployed at scale and made available to the widest possible patient population.

Explore the features of RMS’s diabetes stem cell therapy.